Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | JUN | P05412 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5759836 | 0.97 | KDM4E (0.64) | KDM4ELMNAHTTL3MBTL1MEN1 | |
| SCHEMBL17642998 | 0.81 | MEN1 (0.68) | LMNAHTTMEN1KMT2AMAPT | |
| SCHEMBL5755184 | 0.81 | MEN1 (0.46) | KDM4ELMNAHTTL3MBTL1MEN1 | |
| SCHEMBL31276870 | 0.80 | KDM4E (0.70) | KDM4ELMNAHTTL3MBTL1MEN1 | |
| SCHEMBL15302024 | 0.80 | NPC1 (0.70) | KDM4ELMNAHTTL3MBTL1MAPT | |
| SCHEMBL2566654 | 0.80 | MAPT (0.62) | KDM4EMEN1KMT2AMAPTHSP90AA1 | |
| SCHEMBL5807064 | 0.80 | KDM4E (0.58) | KDM4ELMNAHTTL3MBTL1MEN1 | |
| SCHEMBL17643003 | 0.79 | MEN1 (0.68) | KDM4ELMNAHTTMEN1KMT2A | |
| SCHEMBL5791751 | 0.78 | MEN1 (0.56) | KDM4ELMNAHTTMEN1KMT2A | |
| SCHEMBL14571460 | 0.77 | KMT2A (0.80) | KDM4ELMNAHTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1553947-A4 | QUINAZOLINONES AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-11-29 | — | — | EP | claimed |
| EP-1553947-A2 | QUINAZOLINONES AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-07-20 | — | — | EP | claimed |
| US-20040132732-A1 | Quinazolinones and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-08 | — | — | US | claimed |
| WO-2004037176-A2 | QUINAZOLINONES AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-06 | — | — | WO | claimed |
| EP-1553947-A4 | QUINAZOLINONES AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-11-29 | — | — | EP | disclosed |
| EP-1553947-A2 | QUINAZOLINONES AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-07-20 | — | — | EP | disclosed |
| US-20040132732-A1 | Quinazolinones and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-08 | — | — | US | disclosed |
| WO-2004037176-A2 | QUINAZOLINONES AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132732-A1 | Quinazolinones and derivatives thereof as factor Xa inhibitors | F12, TFPI, SERPINC1 | KDM4E 2809/4885LMNA 892/4885HTT 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.